PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35527461-3	2022	The cells were intervened by PKC agonist (PMA), PKCalpha inhibitor (safingol), PKCbetaI inhibitor (Go6976) and PKCbetaII inhibitor (LY333531) respectively, and the changes in protein expressions of cPKCs, and the phosphorylation levels of ERK1/2 and Akt were observed by immunoblotting under the condition of normal oxygen or hypoxia.	ruboxistaurin	132-140	thymoma viral proto-oncogene 1	Mus musculus	250-253	
35527461-11	2022	Using Western blotting, we also observed that after being inhibited by safingol, Go6976 and LY333531 respectively, the phosphorylation levels of ERK1/2 and Akt in PASMCs induced by hypoxia was significantly lower than the control group.	ruboxistaurin	92-100	thymoma viral proto-oncogene 1	Mus musculus	156-159	
29440456-13	2018	The expressions of phospho-Akt (p-Akt), phospho-eNOS (p-eNOS), and VEGF increased significantly in diabetic mice on ruboxistaurin treatment.	ruboxistaurin	116-129	thymoma viral proto-oncogene 1	Mus musculus	27-30	
29440456-13	2018	The expressions of phospho-Akt (p-Akt), phospho-eNOS (p-eNOS), and VEGF increased significantly in diabetic mice on ruboxistaurin treatment.	ruboxistaurin	116-129	thymoma viral proto-oncogene 1	Mus musculus	34-37	
19825373-0	2010	Ruboxistaurin, a PKCbeta inhibitor, inhibits retinal neovascularization via suppression of phosphorylation of ERK1/2 and Akt.	ruboxistaurin	0-13	thymoma viral proto-oncogene 1	Mus musculus	121-124	
19825373-9	2010	These findings indicate that ruboxistaurin has anti-angiogenic effects both in vitro and in vivo that are exerted partly via suppressing the phosphorylation of ERK1/2 and Akt.	ruboxistaurin	29-42	thymoma viral proto-oncogene 1	Mus musculus	171-174